CT和MRI对肝右叶发育不良的诊断价值探讨

doi:10.3969/j.issn.1672-5069.2016.01.019

摘要/Abstract

摘要： 目的探讨电子计算机断层扫描（CT）和磁共振成像（MRI）对肝右叶发育不良的诊断价值。方法选取24例在本院行CT和MRI扫描的肝右叶发育不良患者,结合文献资料综合分析患者肝脏CT和MRI影像学检查特点。结果本组肝右叶发育不良患者24例,男性 8例,女性16例;年龄在40~85岁,平均年龄为（60.7±3.2）岁;采用MRI检查发现者6例,采用CT检查发现者18例,两种检查方法诊断者4例;影像学检查表现为肝右叶体积缩小,门静脉及其分支出现细小或者缺如。肝左叶增大18例,肝左叶正常6例。尾状叶体积缩小,伴有尾叶内发生胆汁淤积3例,尾状叶体积增大者15例。14例出现肝外胆管结石,12例胆囊右后旋,8例患者行胆囊切除。24例患者均出现了肝内胆管扩张,12例出现脾脏增大,9例伴发肝脏肿瘤,并发腹膜转移1例。结论CT和MRI检查对于诊断肝右叶发育不良具有重要的临床意义。

关键词: 肝右叶发育不良, 体层摄影术, X线计算机, 磁共振成像, 诊断

Abstract: Objective To investigate the application of computed tomography（CT） and magnetic resonance imaging （MRI） in diagnosis of agenesis of right hepatic lobe. Method Twenty-four patients with agenesis of right hepatic lobe were recruited in our hospital,and they were all checked-up by CT and MRI. Results Our series included eight men,and sixteen women,with the average age of（60.7±3.2） yr-old;the agenesis of right hepatic lobe were diagnosed by MRI in 6,by CT in 18,and by both in 4;the imaging showed shrunk volume of right lobe,narrow portal vein and even lost its branches;left hepatic lobe enlarged in 18,and with normal left hepatic lobe in 6;hepatic caudate lobe shrank in 3,and enlarged in 15;extrahepatic bile duct stone in 14,dislocation of gall bladder in 12;all patients had cholangiectasis,12 had splenomegaly,and 9 had neoplasm. Conclusion The application of CT and MR imaging for the diagnosis of right lobe dysplasia have important clinical significance.

Key words: Agenesis of the right hepatic lobe, Computed tomography, Magnetic resonance, Diagnosis

刘浏, 潘轲. CT和MRI对肝右叶发育不良的诊断价值探讨[J]. 实用肝脏病杂志, 2016, 19(1): 77-80.

Liu Liu, Pan Ke. Application of computed tomography and magnetic resonance in diagnosis of agenesis of right hepatic lobe[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 77-80.

参考文献

[1] Patel1 K,Bedossa P,Castera L. Diagnosis of liver fibrosis: Present and future. Liver Dis,2015,35（2）:166-183.
[2] Baranova A,Lal P,Birerdinc A,et al. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol,2011,11（12）:91-135.
[3] Benyon RC,Arthur MJ. ExtraceUular matrix degradation and the role of hepatic stellate ceas. Semin Liver Dis,2001,21（3）:373-384.
[4] Walsh KM,Fletcher A,MacSween RN,et al. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol,2000,32（2）:325-330.
[5] Roderfeld M,Hemmann S,Roeb E. Mechanisms of fibrinolysis in chronic liver injury （with special emphasis on MMPs and TIMPs）. Z Gastroenterol,2007,45（1）:25-33.
[6] Schwettmann L,Wehmeier M,Jokovic D,et al. Hepatic expression of a disintegrin and metalloproteinase（ADAM） and ADAMs with thrombospondin motives（ADAM-TS） enzymes in patients with chronic liver disease. J Hepatol,2008,49（2）:243-250.
[7] Boeker KH,Haberkom CI,Michels D,et al. Diagnostic potential of circulating TIMP-l and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta,2002,316（1-2）:7l-81.
[8] 徐铭益,陆伦根. 肝纤维化血清学标志物及诊断模型的诊断价值. 中华肝脏病杂志,2014,22（9）:647-649.
[9] Imbert-Bismut F,Ratziu V,Pieroni L,et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection:A prospective study. Lancet,2001,357（9262）:1069-1075.
[10] Forns X,Ampurdanes S,Llovet JM,et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatoogy,2002,36（4 Pt 1）:986-992.
[11] Cales P,Oberti F,Michalak S,et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology,2005,42（6）:1373-1381.
[12] Adams LA,Bulsara M,Rossi E,et al. Hepascore:An accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem,2005,51（10）:1867-1873.
[13] Zeng MD,Lu LG,Mao YM,et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology,2005,42（6）:1437-1445.
[14] Qu Y,Gao CF,Zhou K,et al. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Ann Hepatol,2012,11（2）:202-212.
[15] Wang Y,Xu MY,Zheng RD,et al. Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters. Hepatol Res,2013,43（5）:441-451.
[16] Zhou K,Gao CF,Zhao YP,et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol,2010,25（9）:1569-1577.
[17] Sebastiani G,Vario A,Guido M,et al. Sequential algorithms combining noninvasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol,2007,13（4）:525-531.
[18] Sebastiani G,Halfon P,Castera L,et al. SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology,2009,49（6）:1821-1827.
[19] Naveau S,Gaude G,Asnacios A,et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology,2009,49（1）:97-105.
[20] Guha IN,Parkes J,Roderick P,et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease:Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology,2008,47（2）:455-460.
[21] Mayo MJ,Parkes J,Adams-Huet B,et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology,2008,48（5）:1549-1557.
[22] Crawford DH,Murphy TL,Ramm LE,et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology,2009,49（2）:418-425.
[23] XU MY,QU Y,JIA XF,et al. Serum proteomic MRM identify peptideions of transferrin as new fibrosis markers in chronic hepatitis B. Biomed Pharmacother,2013,67（7）:561-567.
[24] Qu Y,Gao CF,Zhou K,et al. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Ann Hepatol,2012,11（2）:202-212.
[25] Xu MY,Jia XF,Qu Y,et al. Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B. J Transl Med,2013,11（9）:234.
[26] Venugopal SK,Jiang J,Kim TH,et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells,and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol,2010,298（1）:G101-G106.
[27] Guo CJ,Pan Q,Li DG,et al. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell:An essential role for apoptosis. J Hepatol,2009,50（4）:766-778.
[28] Murakami Y,Toyoda H,Tanaka M,et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One,2011,6（1）:e16081.
[29] Ninomiya M,Kondo Y,Funayama R,et al. Distinct microRNAs expression profile biliary cirrhosis and evaluation of miR-505-3P and miR-197-3p as novel biomarkers. PLoS One,2013,8（6）:e66086.
[30] 徐铭益,张启迪,李郑红,等. 慢性乙型肝炎肝纤维化患者肝组织基因表达谱和功能分类. 肝脏,2013,18（7）：435-438.
[31] Schuppan D,Pinzani M. Anti-fibrotic therapy: lost in translation? J Hepatol,2012,56（1）:66-77.
[32] Trepo E,Potthoff A,Pradat P,et al. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol,2011,55（1）:38-44.
[33] Estrabaud E,Vidaud M,Marcellin P,et al. Genomics and HCV infection:progression of fibrosis and treatment response. J Hepatol,2012,57（5）:1110-1125.
[34] Dongiovanni P,Donati B,Fares R,et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol,2013,19（41）:6969-6978.
[35] Hannivoort RA,Hernandez-Gea V,Friedman SL. Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogen Tissue Rep,2012,5（1）:1.